TABLE 8

Antiviral activity of the combination of pibrentasvir with HCV inhibitors of other classes in vitro

HCV inhibitoraSynergy vol (μM2%)Antagonism vol (μM2%)Interaction type
IFN-α43 ± 4.7−1.4 ± 0.1Minor synergy
RBV29 ± 7.4−2.8 ± 0.3Minor synergy
Glecaprevir (NS3/4A PI)73 ± 17−1.9 ± 0.4Moderate synergy
  • a IFN-α, interferon alpha; RBV, ribavirin; PI, protease inhibitor.